



Bisphosphonate: Zoledronic acid (Reclast) Infusion Order

AUTHORIZATION IS GRANTED TO DISPENSE AND ADMINISTER AN ALTERNATE DRUG PRODUCT ACCEPTABLE TO THE MEDICAL STAFF'S PHARMACY COMMITTEE UNLESS THE DRUG PRODUCT IS SPECIFICALLY CIRCLED						
		Treatment Date:		llergies/Reactions		
	onths (max of 1 dose per order)					
Diagnosis (Required):			ICD-10 Code (Required):			
Height (cm):	I ah ardara (unless of	herwise specified).	MP required within 20	O days of treatme	nt All other labs	
Height (cm): Lab orders (unless otherwise specified): CMP required within 30 days of treatment. All other per provider.						
	Consider ordering urine pregnancy test within 96 hours prior to treatment in women of child-bearing					
W. I. (4.)	potential			T = === :		
Weight (kg):	HOLD treatment &			Emetic Risk: Minimal		
• Corrected calcium < 8		1 < 8 mg/dL		Monitor: • Renal function		
[Corrected calcium(mg/c dL)]		g/aL) = 0.8(4.0 – albumli	(dL) = 0.8(4.0 - albumin) + calcium(mg/		For hypocalcemia	
	• Ionized calcium < 4 mg			For arthralgias/myalgias		
	• CrCl < 35 mL/min			• Osteonecrosis of jaw		
MEDICATION DOSAGE		E	ADMINISTRAT INSTRUCTIO		REQUENCY	
			INSTRUCTIO	JNS .		
Zoledronic acid	5 mg	5 mg		mL IV	x 1 dose,	
(Reclast)			over 15 minutes		Yearly	
IF PATIENT HAS A HYPERSENSITIVITY REACTION, BEGIN HYPERSENSITIVITY PROTOCOL						
HYDRATION ORDERS						
THE TRAITON ORDERS						
ADDITIONAL ORDERS						
☐ Patient taking calcium	supplementation					
(Recommendation: Calcium	1000 mg + Vitamin D 400 Intern	national Units per day a	and ≥ 50 years old: Calc	eium 1200-1500 mg	+ Vitamin D 800	
International Units per day)						
Discontinue IV upon completion of treatment, flush order per			ovider's full signatur	ro(s) is to follow	the order	
protocol.		тпе рі	ovider s fuir signatur	rc(s) is to follow	ine-order	
Reference: LexiComp						
Patient Name:						
Date of Birth: / /		Signat	ure	Date	Time	
		Printe	d Name:			

Bisphosphonate: Zoledronic acid (Reclast) Yearly